PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) Chemical Structure

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 43 Publications

12 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

    LY294002 (10 μM for 12 h)- and PD184352 (10 μM for 12 h)-treated Her2-transfected DU145 and PC3 cells, respectively, showed reciprocal feedback inhibition between the PI3K/AKT and MEK/ERK path ways

    Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck.

  • The effect of CI-1040 on cell viability of molecular apocrine lines. MTT assay to measure cell viability in MDA-MB-453 cell line after treatment with CI-1040 (CI) at 2 to 25 μM concentrations. MTT assay to measure cell viability in HCC-1954 cell line after treatment with CI-1040 at 2 to 25 μM concentrations.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

    Combination indices (CI) for flutamide (FLU) and CI-1040 combination therapy in MDA-MB-453-R line using MTT assay. Therapies were carried out with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM (CI-5 and CL-10). The concentrations of fluatmide and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2SEM. Western blot analysis was used to measure the phosphorylated and total ERK levels in MDA-MB-453-R line following combination therapies with CI-1040 (5 μM)/flutamide (5 μM) and CI-1040 (5 μM)/flutamide (10 μM). RR values were measured relative to the untreated MDA-MB-453-R line.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

  • Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-μM concentration.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    Relative expression of AR using RT-PCR in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (MEK Inh) at 10-μMconcentration for 24 hours. Expression is relative to that of vehicle-treated cells (CTL). *P < .01 is for CI-1040 versus control. Error bars,±2 SEMs.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • Synergistic effect of AR and mitogen-activated protein kinase kinase inhibitors on cell viability. (A) MTT assay to measure cell viability in MDA-MB-453 cell line after monotherapies and combination treatments with flutamide (FLU) and CI-1040 (CI) at 5 and 10 μΜ concentrations. CTL: control. Error bars: ±2 SEM. (B) Combination indices (CI) for flutamide and CI-1040 combination therapy in MDA-MB-453 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM. The concentrations of FLU and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2 SEM. (C) Combination indices for flutamide and CI-1040 combination therapy in HCC-1954 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 20 and 40 μM with each concentration of CI-1040 at 5 and 10 μM. (D) Combination indices for flutamide and CI-1040 combination therapy in HCC-202 cell line using MTT assay at concentrations described in Figure 2C.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

    The bar chart represents the relative numbers of third-round colonies of primary hematopoietic cells transduced with MLL-AF9 with treatment of compound PD184352 (CI-1040, 10 μM, a MEK inhibitor) and SB216763 (10 μM, GSK-3 inhibitor). The synergic effect between compounds CI-1040 and SB-216763 has been observed.

     

     

    2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Features First MEK inhibitor to begin clinical development.
Targets
MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
17 nM 17 nM
In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H9 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMEKyO|Yh|ryP MX7TRW5ITVJ?
CHP-212 M4XKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\EWHRKSzVyPUCuNFI5QDVizszN NFrTOXpUSU6JRWK=
EoL-1-cell MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TZUGlEPTB;MD6wOFE2OiEQvF2= NFHHSWtUSU6JRWK=
DU-4475 M{nnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETZPVZKSzVyPUCuNFc2QTlizszN MWnTRW5ITVJ?
MMAC-SF NYn6UYRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMUC5O|Qh|ryP MWjTRW5ITVJ?
AGS NUXaZ4tkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMUG3NVMh|ryP MmP0V2FPT0WU
M14 NEfNO|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMUW0Olgh|ryP MmH1V2FPT0WU
CP50-MEL-B NV\hfIxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LpXmlEPTB;MD6xO|I2PCEQvF2= NFr0O5NUSU6JRWK=
C32 M3P1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGOwcoVKSzVyPUCuNVkxPzJizszN MmDXV2FPT0WU
KMOE-2 MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkH4TWM2OD1yLkG5O|k2KM7:TR?= NG\YRZZUSU6JRWK=
A101D MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[0TWM2OD1yLkKxOEDPxE1? MnHYV2FPT0WU
KM12 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELBcHNKSzVyPUCuNlQxPTdizszN NGDBZ5ZUSU6JRWK=
HSC-4 NXezTGNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rHXWlEPTB;MD6yOFM6PSEQvF2= NWTENYs6W0GQR1XS
NOMO-1 MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwMkW3OFIh|ryP MkC2V2FPT0WU
MZ7-mel NGjBUpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvqTWM2OD1yLkK2N|Qh|ryP M{XpZ3NCVkeHUh?=
ACN NGPYTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHDbG1KSzVyPUCuNlY4OzdizszN NXjWb2lyW0GQR1XS
MEL-HO NVf6c2xnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLzcm5KSzVyPUCuNlc3PTJizszN MVfTRW5ITVJ?
BHT-101 M3rUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTmd|E2UUN3ME2wMlI5PjB4IN88US=> NEDjVGlUSU6JRWK=
SK-MEL-28 NH73WIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrwTWM2OD1yLkOwOFA6KM7:TR?= MnvQV2FPT0WU
KG-1 NInVbXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwM{C2Olgh|ryP NFru[3VUSU6JRWK=
COLO-679 NVniWnc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET6R3pKSzVyPUCuN|I4OiEQvF2= M1n0fXNCVkeHUh?=
SK-MEL-24 NHzJfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLjXVZTUUN3ME2wMlMzQDF|IN88US=> NV7zW|RvW0GQR1XS
G-361 M2rEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TTdGlEPTB;MD6zOlc6PSEQvF2= M{TWOHNCVkeHUh?=
KY821 NFnJW|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDqTWM2OD1yLkO3PVEh|ryP NUjGdYNEW0GQR1XS
KASUMI-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwM{m5JO69VQ>? NFn0ZlJUSU6JRWK=
HL-60 NWjyZ|NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfETWM2OD1yLkSxNVA4KM7:TR?= MYXTRW5ITVJ?
K5 M3ewemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XuN2lEPTB;MD60N|EyPyEQvF2= MoP2V2FPT0WU
KU812 NGfKT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HNWGlEPTB;MD60OVI6QSEQvF2= NHXlPWpUSU6JRWK=
SH-4 NFTLe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG4TWM2OD1yLkS2NlU3KM7:TR?= MoTFV2FPT0WU
HTC-C3 NEDhR|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r4emlEPTB;MD60OlU{OSEQvF2= NH;MfWlUSU6JRWK=
CP66-MEL M3\UT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwNEi4NFkh|ryP M2O0fXNCVkeHUh?=
WM-115 M3zZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwNEmyOVch|ryP MXnTRW5ITVJ?
A2780 NF;GNWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHWVVJKSzVyPUCuOFk5OjNizszN MYjTRW5ITVJ?
P12-ICHIKAWA NHPqR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK3dItUUUN3ME2wMlYyOjJzIN88US=> MkXEV2FPT0WU
HMV-II M2Djc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[2TWM2OD1yLk[0OFY2KM7:TR?= MnzpV2FPT0WU
HT-144 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwNkS2OVch|ryP NYq0Zo1rW0GQR1XS
LB2518-MEL NXHuXXdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe0OmhKSzVyPUCuO|E3OzJizszN NXzwWopzW0GQR1XS
NCI-SNU-1 NVnHSWpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj4UIF2UUN3ME2wMlc2PDN|IN88US=> M3j1cXNCVkeHUh?=
C2BBe1 MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFriWIFKSzVyPUCuPFExOjNizszN MojGV2FPT0WU
PSN1 M{SzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\1d2lEPTB;MD65OlE6PiEQvF2= MlHxV2FPT0WU
UACC-257 NETqW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHlZmlKSzVyPUCuPVY1PzNizszN MmHlV2FPT0WU
RVH-421 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\JTWM2OD1yLkm3NVgh|ryP M2LFXnNCVkeHUh?=
GP5d MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:3e2lEPTB;MD65PFMxQCEQvF2= M1LlO3NCVkeHUh?=
TYK-nu MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXoVm1KSzVyPUGuNFMyPzJizszN NH3KO3dUSU6JRWK=
SK-N-AS M1XZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP0RnozUUN3ME2xMlA4QTR5IN88US=> NVzO[mI1W0GQR1XS
SW620 MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nobmlEPTB;MT6xN|U{PCEQvF2= MmP2V2FPT0WU
HuP-T4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITNfVFKSzVyPUGuNVg{PTlizszN MV3TRW5ITVJ?
A549 NETMb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTFwMUm1O|Yh|ryP M1;3dXNCVkeHUh?=
Mewo NIPiV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFwMkCyO|Yh|ryP MWDTRW5ITVJ?
ONS-76 MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rtSGlEPTB;MT6yNlA1QSEQvF2= M1Tlc3NCVkeHUh?=
SK-MEL-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrTTWM2OD1zLkKzOFE6KM7:TR?= M2fsZ3NCVkeHUh?=
RCM-1 M3rrPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwMkSwOFch|ryP NWjqdWNwW0GQR1XS
H-EMC-SS NUTh[XcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXL[2c5UUN3ME2xMlI6PjB6IN88US=> MVjTRW5ITVJ?
NCI-H2291 MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TtRmlEPTB;MT6zNlU{PiEQvF2= M2P2N3NCVkeHUh?=
SW1463 M1viVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFwM{O3NlEh|ryP NInPU49USU6JRWK=
LS-411N M1\TZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHPRnI3UUN3ME2xMlQxPTF5IN88US=> M3zZW3NCVkeHUh?=
BV-173 M1HnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrJ[YI1UUN3ME2xMlQ1ODF3IN88US=> Mnf2V2FPT0WU
LS-513 M3rTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFwNEWxPVIh|ryP MYHTRW5ITVJ?
LoVo NFjVSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITR[3dKSzVyPUGuOFY{QTlizszN Ml60V2FPT0WU
HO-1-N-1 M4fqOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHmbIE5UUN3ME2xMlUyPjN2IN88US=> MljrV2FPT0WU
ML-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHZTWM2OD1zLkWyPFY5KM7:TR?= NFrBVlZUSU6JRWK=
NCI-H1437 M1TaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M373SGlEPTB;MT61OVI4PSEQvF2= MkDEV2FPT0WU
SW1116 MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYexcWt5UUN3ME2xMlU3Ozl6IN88US=> NFrZNXRUSU6JRWK=
A4-Fuk NWm2OGZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTFwNUewOFUh|ryP NHn0S5FUSU6JRWK=
HD-MY-Z NV;zNFFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXWTWM2OD1zLkW3N|c3KM7:TR?= NVrNfphOW0GQR1XS
SK-MEL-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TLS2lEPTB;MT61O|Q2QSEQvF2= MYjTRW5ITVJ?
RT-112 M4S4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTFwNUi5OVIh|ryP NF6xe2dUSU6JRWK=
COLO-829 NUTxTHRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TCdGlEPTB;MT62NlI{OiEQvF2= M2nyTXNCVkeHUh?=
OVCAR-5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vwU2lEPTB;MT63O|Y5PyEQvF2= NGjGNZRUSU6JRWK=
NB69 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmWyTWM2OD1zLke4OFY6KM7:TR?= MWHTRW5ITVJ?
NCI-H292 NXH3eJEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\ETWM2OD1zLki2Olk6KM7:TR?= NGrvSG5USU6JRWK=
LOXIMVI M3m4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PEbmlEPTB;MT64PVQzPyEQvF2= MUnTRW5ITVJ?
BPH-1 M1rSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLxW5lKSzVyPUGuPFk2QTFizszN NVz3SZhtW0GQR1XS
A375 NInMVY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTFwOEm3NVQh|ryP MojsV2FPT0WU
LCLC-97TM1 NGr0fphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Tw[2lEPTB;MT65NlI2PiEQvF2= MkXRV2FPT0WU
RXF393 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zFbGlEPTB;MT65O|g5PyEQvF2= MV3TRW5ITVJ?
HCC70 NEPBSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJwMEK0NlYh|ryP NH\CRpNUSU6JRWK=
EM-2 Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJwMEexPVgh|ryP NHnyN2RUSU6JRWK=
MZ2-MEL MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;1OYFvUUN3ME2yMlEyOTJ5IN88US=> MX3TRW5ITVJ?
HN MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJwMU[yO|gh|ryP NV\s[IJqW0GQR1XS
A2058 NEDKOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTQTWM2OD1{LkG5Nlc6KM7:TR?= NUTOWI5NW0GQR1XS
NB7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlu5TWM2OD1{LkO0NFg3KM7:TR?= MYTTRW5ITVJ?
DOK MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJwM{W3O|Mh|ryP M2HaPHNCVkeHUh?=
CAL-27 MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TJS2lEPTB;Mj6zPVI{PiEQvF2= MY\TRW5ITVJ?
BB65-RCC MkO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr5VYlKSzVyPUKuOFA3PzRizszN MXLTRW5ITVJ?
RD M1TsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPOS45bUUN3ME2yMlQ1PzJ|IN88US=> NH\CZZdUSU6JRWK=
KNS-62 NGPZSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnwTWM2OD1{LkWxNVY1KM7:TR?= Mn7FV2FPT0WU
EW-13 MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjkN4pKSzVyPUKuOVY{OzlizszN NUTPb3NQW0GQR1XS
DB MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe3fHo5UUN3ME2yMlU5Pzh6IN88US=> M2iwRnNCVkeHUh?=
HCC2218 M4O0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jZTmlEPTB;Mj62OFc4QCEQvF2= NHjqVXZUSU6JRWK=
L-363 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW2dlFKSzVyPUKuO|Q{PyEQvF2= NFPYRo5USU6JRWK=
CHL-1 NX7yU5pTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\CSWlEPTB;Mj64NFc5PSEQvF2= MWTTRW5ITVJ?
BFTC-905 MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVKzWY44UUN3ME2yMlgzPTNizszN NFTT[5BUSU6JRWK=
HCE-T Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzFXmtKSzVyPUKuPFMzPjRizszN MmO1V2FPT0WU
COLO-792 MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fKWGlEPTB;Mj64OFAzPyEQvF2= NGfFWFhUSU6JRWK=
LB2241-RCC M4nrbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojITWM2OD1{Lki1PFk{KM7:TR?= NGj2SlZUSU6JRWK=
CAL-39 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjXdlUyUUN3ME2yMlg6QTl7IN88US=> M1r3WXNCVkeHUh?=
T-24 MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLxTWM2OD1{LkmxNVEzKM7:TR?= MmjWV2FPT0WU
NCI-H727 MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fhb2lEPTB;Mj65NVc6PiEQvF2= NXvzcHNMW0GQR1XS
Ca9-22 MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;4PZJKSzVyPUKuPVczPTVizszN MY\TRW5ITVJ?
MIA-PaCa-2 M2ezOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL5TWM2OD1|LkCwO|gyKM7:TR?= NH7XdotUSU6JRWK=
HT-1080 MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHT6epJKSzVyPUOuNFE6QTdizszN M3T5PXNCVkeHUh?=
D-423MG NEjQb4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vzZ2lEPTB;Mz6wO|c2OyEQvF2= MULTRW5ITVJ?
LAMA-84 Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTNwMUO1PEDPxE1? M2e3bXNCVkeHUh?=
SW780 NXPMRmNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7lTnBKSzVyPUOuNVQzOjlizszN M{XURnNCVkeHUh?=
KU-19-19 M3freGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTNwMUewN|Qh|ryP NXG0UYkzW0GQR1XS
COLO-741 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rMWmlEPTB;Mz6xPFY4OyEQvF2= NYPRWnF[W0GQR1XS
HSC-3 MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTNwMkOxOVEh|ryP MWjTRW5ITVJ?
SN12C MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfxRWNKSzVyPUOuNlQ4ODFizszN MoKxV2FPT0WU
786-0 M2myUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTNwMkeyOFMh|ryP MYDTRW5ITVJ?
GAK Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn5fXJKSzVyPUOuN|I2PjFizszN MmXxV2FPT0WU
PANC-03-27 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTNwM{WwOFUh|ryP MlHNV2FPT0WU
CTB-1 MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHjTWM2OD1|LkS3NFQ4KM7:TR?= M2PqZnNCVkeHUh?=
A427 M3;MPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTNwNUm1OVYh|ryP NWrzU4RpW0GQR1XS
EGI-1 M3S3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTNwNkC1PFMh|ryP MlvrV2FPT0WU
U-2-OS M33VSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O3cmlEPTB;Mz62O|I2PiEQvF2= MX7TRW5ITVJ?
NCI-SNU-5 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTNwNke3N{DPxE1? NXv0UG01W0GQR1XS
SK-LU-1 M1;5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4OyfWlEPTB;Mz62PFc6QCEQvF2= MlHzV2FPT0WU
697 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LOcmlEPTB;Mz62PVYxOyEQvF2= NYTDfHQ4W0GQR1XS
HPAF-II MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTNwN{W0PUDPxE1? NELIbndUSU6JRWK=
NCI-H2087 Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X4bmlEPTB;Mz64OFY4OiEQvF2= M{D4PHNCVkeHUh?=
SK-MEL-3 NXj1c2RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfRfWh2UUN3ME2zMlg2OTV2IN88US=> MWDTRW5ITVJ?
CGTH-W-1 NF7HdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvXTWM2OD1|Lki1O|I2KM7:TR?= NGD5eYRUSU6JRWK=
8505C MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\CZXlNUUN3ME2zMlkxODd6IN88US=> NYDJem83W0GQR1XS
GAMG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLMb|NKSzVyPUSuNFI{PzdizszN NH:4UZdUSU6JRWK=
SW626 NWPFc4x3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTrbnFPUUN3ME20MlA1PDhizszN MkCxV2FPT0WU
CAL-62 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPlTWM2OD12LkC3OFMh|ryP NWX5eGtLW0GQR1XS
MHH-PREB-1 MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn2TWM2OD12LkGyNVEyKM7:TR?= NV7nc5hyW0GQR1XS
RPMI-7951 NGjGV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPldo1KSzVyPUSuNlU2QDlizszN NXznNndWW0GQR1XS
HOP-92 MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTRwMkW2O{DPxE1? M4SyeHNCVkeHUh?=
MDA-MB-231 M2LyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPUTWM2OD12LkK5NlI{KM7:TR?= M{XFcnNCVkeHUh?=
LAN-6 MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvHeoZKSzVyPUSuN|E3OzdizszN M4XmfHNCVkeHUh?=
ALL-PO NVvXOZBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TlRmlEPTB;ND6zOlE2PiEQvF2= MVLTRW5ITVJ?
HH MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTRwNEG1PVch|ryP M2DSNHNCVkeHUh?=
IGROV-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHPWnZbUUN3ME20MlQ2OTdzIN88US=> M4nzeHNCVkeHUh?=
NCI-H358 M3fVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;GTWM2OD12LkS1N|g2KM7:TR?= NWTNfnFWW0GQR1XS
NB5 NW\pUnlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fxemlEPTB;ND62NFM3QSEQvF2= MWPTRW5ITVJ?
NCI-H747 NXnmZXVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTRwNki4NFch|ryP M3PVT3NCVkeHUh?=
NH-12 Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\XPYlKSzVyPUSuO|E3OjVizszN MlLhV2FPT0WU
LB1047-RCC NGi5XmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrIXoFsUUN3ME20Mlc{QDF3IN88US=> M1rSSHNCVkeHUh?=
EFO-27 M1zncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[zVWlEPTB;ND63PFY3PyEQvF2= M2W4WHNCVkeHUh?=
EPLC-272H MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTRwOUm2Olkh|ryP NHPUenVUSU6JRWK=
CAL-54 NVjMWXNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX0c|VrUUN3ME21MlAzPjl3IN88US=> M1m0PXNCVkeHUh?=
H4 MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jDN2lEPTB;NT6wOFI2PSEQvF2= MnftV2FPT0WU
MOLT-13 M3H1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTXSmVVUUN3ME21MlA3Pzd4IN88US=> MlnMV2FPT0WU
CAL-33 NFSyTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLmTWM2OD13LkGyN|E4KM7:TR?= MmHJV2FPT0WU
23132-87 NXzWbZd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\oVGVKSzVyPUWuNVY5PzJizszN M1z1NXNCVkeHUh?=
UM-UC-3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzwfFZkUUN3ME21MlE5ODR5IN88US=> NXvvXZp[W0GQR1XS
HuH-7 NFPFPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTVwMkexOFch|ryP NH7m[2dUSU6JRWK=
BCPAP MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XTXmlEPTB;NT6zNlk3QSEQvF2= NF[zNXZUSU6JRWK=
AsPC-1 Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7pfmFKSzVyPUWuN|Y4PjNizszN NXjrOFZ{W0GQR1XS
NCI-H1155 NXnZZWpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTnZW85UUN3ME21MlQxODVzIN88US=> MYTTRW5ITVJ?
GT3TKB MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLZVG1xUUN3ME21MlQ3PTl6IN88US=> NE\nOXBUSU6JRWK=
HCC2998 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDoSpNKSzVyPUWuOFkyODlizszN NI\tTYVUSU6JRWK=
NUGC-3 MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfYO2NKSzVyPUWuOFk{ODJizszN M3r4eHNCVkeHUh?=
Hs-578-T Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTVwNUO3PVQh|ryP M2DkN3NCVkeHUh?=
FADU MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTVwNUW3NlYh|ryP M{\K[3NCVkeHUh?=
NBsusSR NGnpNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLwSmE6UUN3ME21MlU4OTV3IN88US=> M4jpTnNCVkeHUh?=
ME-180 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPMe3Q6UUN3ME21MlU5ODl{IN88US=> MX;TRW5ITVJ?
SW1710 MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlOxTWM2OD13Lk[xOlU1KM7:TR?= NVr0dVdqW0GQR1XS
HuP-T3 M{WwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrOV2NKSzVyPUWuOlIxOjlizszN MnXqV2FPT0WU
HOS NFS4UJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P6[WlEPTB;NT62NlkzOyEQvF2= MVnTRW5ITVJ?
PA-1 NXu2bmlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGL6cWpKSzVyPUWuOlQzPjVizszN NXriWZg5W0GQR1XS
LU-99A MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzkOmlrUUN3ME21MlY3PDVzIN88US=> NH3qZXJUSU6JRWK=
RS4-11 M1O1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHmS29vUUN3ME21MlY3Pzd3IN88US=> M{\KTXNCVkeHUh?=
TE-8 MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTVwNki1N|ch|ryP M{Du[HNCVkeHUh?=
RERF-LC-MS MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTVwNki4NFMh|ryP M2jve3NCVkeHUh?=
MEL-JUSO NHjVNVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXuXW5KSzVyPUWuO|M4QCEQvF2= MUjTRW5ITVJ?
SK-MES-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzuV4U2UUN3ME21Mlg{PTJ6IN88US=> NEnCeFZUSU6JRWK=
D-263MG NV\EZ5g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTVwOEizOVEh|ryP MYLTRW5ITVJ?
NB10 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[0TWM2OD13Lki5OFYh|ryP NFHSRVZUSU6JRWK=
SK-HEP-1 NXLHcoJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTVwOUO0O|Eh|ryP MmDXV2FPT0WU
HT-29 NGrFU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M374XWlEPTB;NT65PFEyQCEQvF2= NUm2eJhJW0GQR1XS
KYSE-140 NHW1UXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3HWmNqUUN3ME22MlAzOTh{IN88US=> NWnJNXZmW0GQR1XS
NCI-H1666 NULMOXQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jZeWlEPTB;Nj6wPFQ3OSEQvF2= NEO1RpVUSU6JRWK=
NCI-H1304 MoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnGTmhMUUN3ME22MlE6QTRizszN NIHDZ29USU6JRWK=
RPMI-8866 MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTZwMkGzNVMh|ryP NHnsSWhUSU6JRWK=
MV-4-11 M4DNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTZwMkOxPVkh|ryP NVnCcHRmW0GQR1XS
A431 NX7Xc285T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13wWGlEPTB;Nj6yOFI6PiEQvF2= NYTGVWduW0GQR1XS
PANC-10-05 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TLUWlEPTB;Nj6yPFM3OyEQvF2= NIjx[4hUSU6JRWK=
TK10 NWTPT2sxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnXUmplUUN3ME22MlMzPjB2IN88US=> NXfiZZJOW0GQR1XS
NCI-H1975 NETpS|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnezTWM2OD14LkS3NlE2KM7:TR?= NYjLXmsxW0GQR1XS
A172 M4\SSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLSTWM2OD14LkS5NVc3KM7:TR?= MkLKV2FPT0WU
D-566MG NH\SWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTZwNUSzNFMh|ryP NIDIPW9USU6JRWK=
NCI-H2122 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTwTIM5UUN3ME22MlYyPTJ6IN88US=> NH7wSGdUSU6JRWK=
COR-L105 NWL4SIlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHztXmFKSzVyPU[uOlUzPzVizszN MmjmV2FPT0WU
AN3-CA NXPvfFZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjlT4dKSzVyPU[uOlg3PDFizszN MlrRV2FPT0WU
Calu-6 MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFqyXWVKSzVyPU[uO|k3QThizszN MVHTRW5ITVJ?
HCT-116 NIH3ZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DMfmlEPTB;Nj64NVI3PCEQvF2= Ml;QV2FPT0WU
MHH-NB-11 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PxV2lEPTB;Nj64OVAxOiEQvF2= MmW0V2FPT0WU
MFE-280 NH\3c3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXPboFKSzVyPU[uPFU6QDNizszN M3LsOHNCVkeHUh?=
SW1088 NX7LdHpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTZwOUG5NVMh|ryP NXn3Z45[W0GQR1XS
SW48 NWq1N41zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[zXFI2UUN3ME22Mlk1PTFizszN NFi5TFdUSU6JRWK=
HuCCT1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;P[YJKSzVyPUeuNFExOzdizszN NFTCW3VUSU6JRWK=
ACHN M13I[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTdwMEK5OFMh|ryP MnW2V2FPT0WU
8305C NFi2W3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXYNpFqUUN3ME23MlA6QTl3IN88US=> MX7TRW5ITVJ?
DoTc2-4510 NYSyO|RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGryUGlKSzVyPUeuNVIyPSEQvF2= M4XGV3NCVkeHUh?=
COR-L23 MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTdwMkS0NkDPxE1? MnLDV2FPT0WU
SK-MEL-30 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\z[WczUUN3ME23MlI2ODh|IN88US=> M33Xd3NCVkeHUh?=
BE-13 NWfOc4h7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jVS2lEPTB;Nz6zN|g{PCEQvF2= M13zdnNCVkeHUh?=
GR-ST MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfzO5hjUUN3ME23MlQxOTd2IN88US=> M17vcXNCVkeHUh?=
LU-135 NVTZcFEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rheGlEPTB;Nz61OVk{QSEQvF2= MV\TRW5ITVJ?
U-266 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTdwNU[yPFYh|ryP MV\TRW5ITVJ?
NCI-H1355 MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXVOnVKSzVyPUeuOVg3OzVizszN M2jISnNCVkeHUh?=
NB14 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTdwNk[2OFIh|ryP MnGxV2FPT0WU
SCC-25 NVz5[Ws1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;OUFZKSzVyPUeuO|A6KM7:TR?= MknUV2FPT0WU
COLO-678 MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXIcWd6UUN3ME23MlcyODd4IN88US=> MXfTRW5ITVJ?
TGBC1TKB MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHN[4ZKSzVyPUeuPFk{QThizszN MkLIV2FPT0WU
IST-MEL1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRThwMEC0NFYh|ryP M3nN[3NCVkeHUh?=
ECC10 M3zoNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRThwMEOzPVUh|ryP MmnVV2FPT0WU
EW-16 NYf3WHQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jY[WlEPTB;OD6wPFQ1PSEQvF2= NIruXnBUSU6JRWK=
DOHH-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;Qe|h3UUN3ME24MlIxODl3IN88US=> MUjTRW5ITVJ?
NCI-H1581 MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRThwMk[zNlMh|ryP Mlz5V2FPT0WU
TE-5 NYnFdlBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTEWVYxUUN3ME24MlQzPDJ7IN88US=> MlPzV2FPT0WU
CAKI-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLNPXliUUN3ME24MlU4OjJ{IN88US=> MmnqV2FPT0WU
A673 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRThwNkOyNFIh|ryP NWnjNpNjW0GQR1XS
CAL-12T NUXYbIdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j1TGlEPTB;OD62OVc2OyEQvF2= NIm3O4VUSU6JRWK=
DBTRG-05MG MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vTdmlEPTB;OD63OFg2QSEQvF2= NVzvRZFtW0GQR1XS
SK-N-FI NIXQdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfoelhQUUN3ME24MlgyOzd7IN88US=> MVHTRW5ITVJ?
K-562 M4DidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRThwOEO5OVch|ryP NFHDWJhUSU6JRWK=
SBC-1 M1rwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHU[I1JUUN3ME24Mlg3PjR3IN88US=> Mk\EV2FPT0WU
ES4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ThRWlEPTB;OD64Olg5PCEQvF2= M2fTfXNCVkeHUh?=
MS-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDVTWM2OD16Lki3OVE4KM7:TR?= MY\TRW5ITVJ?
RKO M{XG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRThwOEmwOVch|ryP MUPTRW5ITVJ?
NCI-H1693 Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXixdFBWUUN3ME24MlkzOTdizszN NGPVVXdUSU6JRWK=
SW954 M2nDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRThwOU[5O|gh|ryP NWmzdll6W0GQR1XS
SK-UT-1 M3PIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[2U44yUUN3ME24Mlk4Pjh|IN88US=> MoPxV2FPT0WU
T98G M{O3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfqWW1KSzVyPUiuPVk5PDZizszN M{XrcnNCVkeHUh?=
NCI-H2126 NYLKV4RkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\PRWlEPTB;OT6wNFgzPiEQvF2= M1PtSnNCVkeHUh?=
TE-12 NHTzcXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTlwMEOzOlch|ryP NEXLUHhUSU6JRWK=
DK-MG MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTlwMkGxPVEh|ryP NHvrXItUSU6JRWK=
MEG-01 NVrwUHVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTlwMkS5N|Eh|ryP NW\k[W15W0GQR1XS
HCC1937 Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTpXFhKSzVyPUmuNlkxQTFizszN MWnTRW5ITVJ?
MKN45 NU\H[XlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\4TWM2OD17LkS1NFY2KM7:TR?= MknnV2FPT0WU
NCI-H1792 M1vS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG2dHBKSzVyPUmuOFUzOTlizszN MnTYV2FPT0WU
SW1417 NFH0cVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTlwNU[4N|ch|ryP NFTYWGVUSU6JRWK=
639-V NWPPTJJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrCOYJKSzVyPUmuOlQ{QDhizszN NFjlSYpUSU6JRWK=
P30-OHK Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTlwNkWzNVYh|ryP M4LHOHNCVkeHUh?=
YKG-1 M37KdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPvTWM2OD17Lke1NFM{KM7:TR?= NULx[5JtW0GQR1XS
KGN M3jIU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPHTWM2OD17LkizO|k2KM7:TR?= M37VdXNCVkeHUh?=
MSTO-211H NIPmW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTlwOUW1Nlkh|ryP Mof5V2FPT0WU
NCI-H1573 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnsTFJKSzVyPUGwMlE2PzRizszN MmXhV2FPT0WU
NCI-H720 MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLIc2hbUUN3ME2xNE4yQTh7IN88US=> MVHTRW5ITVJ?
KARPAS-45 NELQW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjQTlFKSzVyPUGwMlI4QTVizszN M4DObnNCVkeHUh?=
MDA-MB-175-VII M{LPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWGxSYQ3UUN3ME2xNE41QCEQvF2= M2XpdHNCVkeHUh?=
SK-NEP-1 NH[4NpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFyLkS5PFEh|ryP NYDkZXJ{W0GQR1XS
MKN28 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHHXXdVUUN3ME2xNE42OThizszN M1vLRXNCVkeHUh?=
KYSE-520 MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWCyNlJIUUN3ME2xNE42OiEQvF2= NEnZN2ZUSU6JRWK=
KE-37 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDrNXh[UUN3ME2xNE42Ojd{IN88US=> MVrTRW5ITVJ?
VA-ES-BJ NUO4WlBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TRVmlEPTB;MUCuOVY4KM7:TR?= NHLyPZhUSU6JRWK=
CCRF-CEM Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LxbmlEPTB;MUCuOVY5PCEQvF2= NYq3fHU3W0GQR1XS
GMS-10 M{PTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFmwRVhKSzVyPUGwMlYxQTRizszN MnO5V2FPT0WU
NCI-H1623 NEDJelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrCTWM2OD1zMD62N|c6KM7:TR?= NFiwbWxUSU6JRWK=
NEC8 MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFyLke3O|Mh|ryP NHzxNZFUSU6JRWK=
MOLT-16 NVTQb25ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHS2OYtKSzVyPUGwMlgyOTNizszN M3P5XnNCVkeHUh?=
DJM-1 MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlj5TWM2OD1zMT6wN|c6KM7:TR?= M3n5OXNCVkeHUh?=
U251 NGfRZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjXXGRoUUN3ME2xNU4xPDJizszN M1XmSnNCVkeHUh?=
SBC-5 NFvFdWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFzLkG0Olch|ryP NFjPTHlUSU6JRWK=
SW756 NUXCU2F3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTFzLkKxOVQh|ryP MXLTRW5ITVJ?
KS-1 MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fpPWlEPTB;MUGuNlYyQSEQvF2= MVnTRW5ITVJ?
SF295 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPzdmYyUUN3ME2xNU4{OTB2IN88US=> NY\rUo1PW0GQR1XS
YH-13 NX7wdXBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7BelRDUUN3ME2xNU4{OjZ5IN88US=> NHjvVZlUSU6JRWK=
SW837 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TueWlEPTB;MUGuN|UxPiEQvF2= NYLKfnYxW0GQR1XS
KYSE-450 M4fMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnmN3BKSzVyPUGxMlQxPTdizszN MkG1V2FPT0WU
KYSE-180 M4HVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojZTWM2OD1zMT60PFIh|ryP MmnDV2FPT0WU
S-117 M1fFNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnToTWM2OD1zMT60PFk3KM7:TR?= M2\hfXNCVkeHUh?=
KOSC-2 NEDvWZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvReZZtUUN3ME2xNU43OjJ{IN88US=> NV3OVJVqW0GQR1XS
KYSE-270 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\OUXFNUUN3ME2xNU45PzR3IN88US=> NUTmbIZCW0GQR1XS
D-336MG NGL0PJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jlS2lEPTB;MUGuPVA4PSEQvF2= M3PSN3NCVkeHUh?=
KALS-1 NWDhN5d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF{LkCwNVYh|ryP MoL3V2FPT0WU
LB373-MEL-D NGDuTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF{LkC1N|Mh|ryP M2Pub3NCVkeHUh?=
HLE NGrORlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWruWYZ[UUN3ME2xNk4xPTh3IN88US=> NVL6NlZiW0GQR1XS
SJSA-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPx[JBKSzVyPUGyMlA4OzVizszN MVHTRW5ITVJ?
SW1990 NGX1NVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXm2cVhnUUN3ME2xNk4xQTFzIN88US=> NFzJZmxUSU6JRWK=
NOS-1 NGrlfo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPxemdKSzVyPUGyMlE{PTJizszN NHj6OoRUSU6JRWK=
GI-ME-N M3\vZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF{LkKxOlMh|ryP MknpV2FPT0WU
NCI-H1703 NGnNTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTF{LkK2NVYh|ryP MnvhV2FPT0WU
ES7 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LYfmlEPTB;MUKuNlczPCEQvF2= NIrubmZUSU6JRWK=
KYSE-510 MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofTTWM2OD1zMj61NFc6KM7:TR?= MoLoV2FPT0WU
BHY Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIWyV3VKSzVyPUGyMlU{ODdizszN MoqyV2FPT0WU
TCCSUP M2rzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\ETWM2OD1zMj61O|U4KM7:TR?= MXPTRW5ITVJ?
HSC-2 Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfjSnRKSzVyPUGyMlU6QTZizszN M{O3S3NCVkeHUh?=
BEN MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTF{Lk[xOFMh|ryP M{D3c3NCVkeHUh?=
769-P MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TFPGlEPTB;MUKuO|kzPCEQvF2= M1jLenNCVkeHUh?=
HT NY[xW4NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4mwc2lEPTB;MUKuPFM1PiEQvF2= NUjLWWhnW0GQR1XS
LXF-289 NV7tPYRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfWTWM2OD1zMj65OVMyKM7:TR?= MlXtV2FPT0WU
OVCAR-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PoZ2lEPTB;MUKuPVU3PyEQvF2= M{Dhc3NCVkeHUh?=
ATN-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET6XFRKSzVyPUGzMlAyQDRizszN NGrxS|BUSU6JRWK=
8-MG-BA NWjGNHN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHVe3pKSzVyPUGzMlA1PTVizszN NWPJfIJMW0GQR1XS
SW13 NEfJRVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkOwTWM2OD1zMz6xNVY2KM7:TR?= NXPRTHlKW0GQR1XS
NCI-H1092 Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorhTWM2OD1zMz6xOlIh|ryP NUPxVWdUW0GQR1XS
OAW-42 NFTvfFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF|LkG5N|ch|ryP M3W4XXNCVkeHUh?=
NCI-H2452 M{Kyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfR[Y9KSzVyPUGzMlIyPzVizszN MVHTRW5ITVJ?
CAPAN-1 NH;S[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO5[4x4UUN3ME2xN{42PTF2IN88US=> NWXYXpdYW0GQR1XS
NCI-H2009 NWr2XGs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfMcnBnUUN3ME2xN{42QTF7IN88US=> NVntbGZxW0GQR1XS
SF268 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTUcJR4UUN3ME2xN{43OzJ4IN88US=> NHS1TpZUSU6JRWK=
GCIY M3HwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF|Lk[5Nlch|ryP M{G3RnNCVkeHUh?=
OS-RC-2 NXPrSnFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTF|Lkm1NFEh|ryP M3nYPHNCVkeHUh?=
GCT NYjGS3lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4CxUGlEPTB;MUOuPVY6PyEQvF2= NEPIT5hUSU6JRWK=
NB17 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTF2LkC4OUDPxE1? MXzTRW5ITVJ?
NCI-H2030 MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTF2LkG0OlUh|ryP MYHTRW5ITVJ?
HC-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj0TWM2OD1zND6yNFg4KM7:TR?= M1uzZ3NCVkeHUh?=
QIMR-WIL Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjFU4lKSzVyPUG0MlM1OTJizszN NYnlOWxWW0GQR1XS
Capan-2 M37STmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF2LkO3NVQh|ryP NF;xSHFUSU6JRWK=
BALL-1 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHWTWM2OD1zND60OlY2KM7:TR?= M{C1VHNCVkeHUh?=
LS-1034 M{G1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\aTWM2OD1zND62NVUzKM7:TR?= MmLiV2FPT0WU
U-118-MG M1jaeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\4doFKSzVyPUG0MlY{OSEQvF2= NF;LRWVUSU6JRWK=
NCI-H630 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXxPI1nUUN3ME2xOE43PTZ6IN88US=> M2XxVXNCVkeHUh?=
OVCAR-8 NUTUepdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\nT2lEPTB;MUSuO|IxOSEQvF2= NFi4O41USU6JRWK=
NCI-H2347 M4Xu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWSxeXV3UUN3ME2xOE45OjNizszN M4LPV3NCVkeHUh?=
BT-549 NEDtd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXBcYhKSzVyPUG0MlgzQDRizszN NVnN[WF1W0GQR1XS
LB831-BLC NH7rZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT3TWM2OD1zND64PVM1KM7:TR?= NX\MUG5wW0GQR1XS
NCI-H661 M2\NcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\Qe|M5UUN3ME2xOE46PTlizszN MmDlV2FPT0WU
MKN7 M3y4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF3LkCwPVMh|ryP MX\TRW5ITVJ?
U-87-MG NFmxSHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHT[25rUUN3ME2xOU4xQDl5IN88US=> NUm2WJdRW0GQR1XS
OVCAR-4 MknVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTufVZtUUN3ME2xOU4yPDJ2IN88US=> M3fvenNCVkeHUh?=
OE33 NXjFZmx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33ve2lEPTB;MUWuNVcyOSEQvF2= M1vibnNCVkeHUh?=
EC-GI-10 MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHETWM2OD1zNT6yN|U4KM7:TR?= NEX6R2pUSU6JRWK=
AM-38 NYXmN5U3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF3LkK3NVch|ryP NEHnU2tUSU6JRWK=
NCI-H1563 M2TXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnntTWM2OD1zNT6zOFkh|ryP MV7TRW5ITVJ?
SCC-4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn6OmJJUUN3ME2xOU41OTB|IN88US=> NEfGUGxUSU6JRWK=
Detroit562 MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF3LkS1OFch|ryP M3L6WHNCVkeHUh?=
PC-14 NH7XVFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnEZWpxUUN3ME2xOU41QDZ4IN88US=> MX7TRW5ITVJ?
ES3 NF36WIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTF3LkWzOkDPxE1? NHnDToZUSU6JRWK=
OCI-AML2 NH;OeJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3KPYxKSzVyPUG1Mlc3OTRizszN MXXTRW5ITVJ?
LU-134-A MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX76XGZGUUN3ME2xOU46ODF6IN88US=> NFm5fFdUSU6JRWK=
SAS NGjiWotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\JcWlEPTB;MUWuPVM4OyEQvF2= NVnLR4JMW0GQR1XS
TGBC11TKB MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnNNIVTUUN3ME2xOU46PDF2IN88US=> M3juTXNCVkeHUh?=
HOP-62 NEHFOIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETad4RKSzVyPUG1Mlk2QTdizszN MoPHV2FPT0WU
G-401 NYq1fmVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\s[25KSzVyPUG1Mlk3PDlizszN MV\TRW5ITVJ?
NCI-H28 NGS4ZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF4LkC4OVYh|ryP M161[nNCVkeHUh?=
A204 Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj1[3o3UUN3ME2xOk4zODB4IN88US=> NIrlUW1USU6JRWK=
NCI-H1299 NF7rcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf5b4VYUUN3ME2xOk4zOjlzIN88US=> M{PDXXNCVkeHUh?=
VMRC-RCZ MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrHOFNKSzVyPUG2MlI2QTJizszN MWjTRW5ITVJ?
BxPC-3 NVK0SpR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIKzUJNKSzVyPUG2MlI5PTZizszN NYWwT|dSW0GQR1XS
NCI-H2228 NGXWUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTF4LkWxOVgh|ryP NUjES5BIW0GQR1XS
NCI-H23 NVHJb|VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF4Lk[wO|gh|ryP NF7IZphUSU6JRWK=
NKM-1 M{fiTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\XcWlEPTB;MUeuNFE5QSEQvF2= MXPTRW5ITVJ?
KYSE-70 NYfldVlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz6TWM2OD1zNz6yPFkh|ryP M1LBUnNCVkeHUh?=
BB49-HNC Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXW3[HZLUUN3ME2xO{42Pjh4IN88US=> NVK4TVVPW0GQR1XS
SCC-15 MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTF5Lki0O|Mh|ryP M1ftW3NCVkeHUh?=
D-247MG NGHsboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW1fllKSzVyPUG3MlkzPDdizszN NXvj[4M4W0GQR1XS
BB30-HNC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfnTWM2OD1zOD6wN|E5KM7:TR?= MXXTRW5ITVJ?
CAL-85-1 M{[wXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF6LkG4NFkh|ryP NWf2U5pmW0GQR1XS
HT-3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHVTWM2OD1zOD6zPVc4KM7:TR?= MnflV2FPT0WU
KYSE-410 NULQU4J{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MluxTWM2OD1zOD60OVc4KM7:TR?= NWLhSXBsW0GQR1XS
SW982 NYrOS45[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPsZ5NKSzVyPUG4MlU3PDlizszN M3rpR3NCVkeHUh?=
SW962 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF6LkW3NFIh|ryP NV3zNIdvW0GQR1XS
Ramos-2G6-4C10 M37ofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDQN|VLUUN3ME2xPE42QTJ5IN88US=> M3rXRXNCVkeHUh?=
OC-314 M3m2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17HSmlEPTB;MUiuO|M5PCEQvF2= MYDTRW5ITVJ?
LS-123 NGD6dnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFm1cXRKSzVyPUG4Mlc6ODFizszN NEX2ZnNUSU6JRWK=
D-502MG NXTCWlNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV74[lVjUUN3ME2xPE45OTN7IN88US=> MX\TRW5ITVJ?
RO82-W-1 M{DxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HqOWlEPTB;MUiuPFI5QCEQvF2= NXTGT|JIW0GQR1XS
HuO9 MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;VTWM2OD1zOT6xN|c6KM7:TR?= NYHYTWZtW0GQR1XS
ETK-1 M2rUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{THNmlEPTB;MUmuNVgzPyEQvF2= M{HIfnNCVkeHUh?=
SNU-387 MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTF7LkG4PFkh|ryP NE[4XpJUSU6JRWK=
SW1573 M4nkd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHlR|lnUUN3ME2xPU4yQTZ7IN88US=> NGLQNFZUSU6JRWK=
NTERA-S-cl-D1 NUXIWXdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rQfmlEPTB;MUmuNlAxPyEQvF2= MWfTRW5ITVJ?
SF126 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF7LkO1NFIh|ryP NXfMT3RpW0GQR1XS
Calu-3 NI\zcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7pcppKUUN3ME2xPU41OjN5IN88US=> MV3TRW5ITVJ?
NCI-H1048 MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f0PGlEPTB;MkCuN|I3PiEQvF2= MmDGV2FPT0WU
NCI-H226 NX\KdYx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;oTWM2OD1{MD60N|k6KM7:TR?= NVTQS3RmW0GQR1XS
FTC-133 Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXoTWM2OD1{MD60O|A{KM7:TR?= M4\6R3NCVkeHUh?=
SF539 MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHme2lKSzVyPUKwMlUyPzJizszN M1zuO3NCVkeHUh?=
TE-6 M1rSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\Lb|hKSzVyPUKwMlgxPjdizszN M4H0TXNCVkeHUh?=
UMC-11 NWe1ZZNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHLUpZKSzVyPUKwMlkyPjRizszN M4TiZ3NCVkeHUh?=
Becker NWPJdHlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fDbmlEPTB;MkGuNVEyQCEQvF2= NH3ubFRUSU6JRWK=
KP-4 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{S4WmlEPTB;MkGuNVE6PiEQvF2= NYLBSI81W0GQR1XS
ChaGo-K-1 NVzjTZFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\iOYdKSzVyPUKxMlM3OjdizszN M3v6fHNCVkeHUh?=
CFPAC-1 NXrjWIFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17rWWlEPTB;MkGuN|g2QCEQvF2= NYPDOJo4W0GQR1XS
A498 NVn3NVRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPRd3F5UUN3ME2yNU42OzF{IN88US=> MofNV2FPT0WU
NCI-H1755 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly5TWM2OD1{MT62O|QyKM7:TR?= M2nqR3NCVkeHUh?=
TI-73 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLmOG9zUUN3ME2yNk4{OjhizszN NHXw[W1USU6JRWK=
NCI-H441 NYq4epE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\0[WlEPTB;MkKuOVY5QSEQvF2= NV30RplFW0GQR1XS
CaR-1 Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;XfmxKSzVyPUKzMlAzOTNizszN NFrUfnVUSU6JRWK=
HCC1806 NYqyOnk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLyTWM2OD1{Mz6wOVg{KM7:TR?= MX\TRW5ITVJ?
SNU-449 NHnIW2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nF[mlEPTB;MkOuN|I6KM7:TR?= NVrRelkzW0GQR1XS
EKVX NULT[Gp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHhTWM2OD1{Mz6zPVA6KM7:TR?= MXjTRW5ITVJ?
DMS-114 NFXGcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nVbWlEPTB;MkOuOVc3PSEQvF2= NFL4XGJUSU6JRWK=
A704 M{Cx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDGTWM2OD1{Mz62NVA{KM7:TR?= NFLNNmlUSU6JRWK=
LC-2-ad NX;BWIhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJ|Lk[xOFch|ryP M1fCNXNCVkeHUh?=
VM-CUB-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJ|LkezOFEh|ryP M4e1bHNCVkeHUh?=
PC-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e1VGlEPTB;MkSuNFUzPiEQvF2= MWrTRW5ITVJ?
HEL M1nyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\KdZF6UUN3ME2yOE4xQDZ3IN88US=> M{TQVHNCVkeHUh?=
ABC-1 MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPOXVRYUUN3ME2yOE4zPzJ7IN88US=> M3vjXXNCVkeHUh?=
COLO-680N MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq2TGZ[UUN3ME2yOE41PzZ2IN88US=> M1rBTHNCVkeHUh?=
MZ1-PC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJ2Lk[4O{DPxE1? MUnTRW5ITVJ?
NCI-H69 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTnTWM2OD1{ND63N|U1KM7:TR?= M4njXnNCVkeHUh?=
TE-1 MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPvTWM2OD1{NT6wOFk6KM7:TR?= MXrTRW5ITVJ?
EW-3 NGLKOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFW4W4hKSzVyPUK1MlEyOyEQvF2= MYjTRW5ITVJ?
PANC-08-13 MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r6[2lEPTB;MkWuPFExOyEQvF2= NHPFT|JUSU6JRWK=
NMC-G1 NYTaXFdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJ4LkCwPFgh|ryP NHr4d5dUSU6JRWK=
BT-20 NULaSY9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHDN3hyUUN3ME2yOk41PTR|IN88US=> NWW3V45kW0GQR1XS
TGBC24TKB Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn6yTWM2OD1{Nj63N|MyKM7:TR?= MVzTRW5ITVJ?
TE-11 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nlRWlEPTB;Mk[uPVg6PSEQvF2= M4[zWnNCVkeHUh?=
ESS-1 M2r2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJ5LkOyNVYh|ryP NF;IXpFUSU6JRWK=
JVM-3 Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jKTWlEPTB;MkeuOlQ4PSEQvF2= MUPTRW5ITVJ?
C3A MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\WN4FzUUN3ME2yO{45PDl4IN88US=> M{X0XnNCVkeHUh?=
MDA-MB-157 NHTPSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJ5Lki3OVMh|ryP M1jjbnNCVkeHUh?=
KLE MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPvbYlpUUN3ME2yPE4yODV6IN88US=> NYrjV5h2W0GQR1XS
ES1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLSR|l3UUN3ME2yPE4yQDN6IN88US=> NIjXNFdUSU6JRWK=
CAL-120 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnOUYtKSzVyPUK4MlM6QTlizszN MnvRV2FPT0WU
NCI-N87 NFj5VGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHRSlJKSzVyPUK4MlUyODVizszN MmraV2FPT0WU
RPMI-8226 NXPvRWhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJ7LkG4OFMh|ryP MYDTRW5ITVJ?
COR-L88 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJ7LkK0NVkh|ryP MnfmV2FPT0WU
UACC-893 Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[2U2lEPTB;MkmuN|E{PyEQvF2= NV7lWopIW0GQR1XS
C8166 M1i4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XVfGlEPTB;MkmuPVk6PiEQvF2= NEOwO3ZUSU6JRWK=
J82 M{nmXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGwUYt{UUN3ME2zNE45OTR5IN88US=> MkPnV2FPT0WU
PFSK-1 NFfsbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH6VINNUUN3ME2zNU4xPjV7IN88US=> NWnZN3NXW0GQR1XS
COLO-684 NH\FUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHMblhKSzVyPUOxMlQ{PzRizszN M3jKW3NCVkeHUh?=
CAL-72 M2exU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlviTWM2OD1|MT61O|I6KM7:TR?= NX7RWnN1W0GQR1XS
SNB75 NELKVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHXeHhyUUN3ME2zNU45QTdizszN MYTTRW5ITVJ?
MDA-MB-415 NVrlSJFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTNzLkm3OlIh|ryP Mk\jV2FPT0WU
SiHa M1\zO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnySHdKSzVyPUOyMlQ4OTFizszN MlXJV2FPT0WU
NCI-H1648 NFTTbY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PEWGlEPTB;M{KuPVM1PSEQvF2= MU\TRW5ITVJ?
EFO-21 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYGzdWJUUUN3ME2zN{4xODVizszN M4X2fHNCVkeHUh?=
HCC38 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnKxTWM2OD1|Mz6zPFQyKM7:TR?= M3jIUHNCVkeHUh?=
IA-LM NULoeI04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[1N2lEPTB;M{OuO|g5QSEQvF2= MYHTRW5ITVJ?
CTV-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTITWM2OD1|Mz65O|g3KM7:TR?= M1LJUnNCVkeHUh?=
NCI-H446 NHXjVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;oNmFPUUN3ME2zOE4zPjh7IN88US=> Mm\QV2FPT0WU
IST-SL1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTN2Lke0NFgh|ryP NF\Lb5FUSU6JRWK=
EW-22 NVeydmtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33mfWlEPTB;M{SuO|c2QSEQvF2= MkL1V2FPT0WU
JEG-3 NH;Pb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjhTWM2OD1|Nj6xO|Y3KM7:TR?= NETSUJNUSU6JRWK=
LU-65 M4PRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPsRW1tUUN3ME2zOk4zQTh3IN88US=> NH\NXIVUSU6JRWK=
NCI-H596 MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIKxUlZKSzVyPUO2Mlk2QTFizszN NVjiRXM1W0GQR1XS
KNS-81-FD MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTN5LkG0OUDPxE1? MkHZV2FPT0WU
NCI-H1793 NXzTdnhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTN5LkewPFYh|ryP NIr3WHVUSU6JRWK=
NCI-H460 NHrYN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf2TWM2OD1|OD6wPFc{KM7:TR?= NVnKSWRlW0GQR1XS
MPP-89 MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfWTWM2OD1|OT61PFg3KM7:TR?= NWq3bms6W0GQR1XS
D-542MG M1juWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fncmlEPTB;M{muPFQ{PiEQvF2= NH3hZW9USU6JRWK=
JAR NVnqV5J5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorkTWM2OD12MD60O|A2KM7:TR?= NELUXFlUSU6JRWK=
NCI-H209 M1HYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFi4dZdKSzVyPUSwMlY4PyEQvF2= MVXTRW5ITVJ?
G-402 MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPaVHpKSzVyPUSxMlM6QTNizszN NITLSWtUSU6JRWK=
IST-MES1 MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[3R3R[UUN3ME20Nk4yQTN3IN88US=> M3PhNHNCVkeHUh?=
Daoy NFy0ZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnGRXBKSzVyPUSyMlU1PzFizszN MnfIV2FPT0WU
EW-11 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jRSmlEPTB;NEOuNVIyOSEQvF2= MXnTRW5ITVJ?
Saos-2 NEDKN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2CxVWlEPTB;NEOuNVU{PyEQvF2= NYHLfHh2W0GQR1XS
no-10 MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHNblFiUUN3ME20N{4yPzB{IN88US=> NVnv[XVmW0GQR1XS
HCC1395 MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrTcpM5UUN3ME20N{41PjR2IN88US=> MV;TRW5ITVJ?
HCE-4 Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonqTWM2OD12Mz63OlY1KM7:TR?= MlLKV2FPT0WU
EW-1 NHjHeFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzSTVJKSzVyPUSzMlgxPDlizszN NVO1S|FqW0GQR1XS
OCUB-M MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj4S4tCUUN3ME20OE4{PjN6IN88US=> NGO0NZBUSU6JRWK=
IGR-1 NXzVcIdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULYVnFnUUN3ME20OE41OTF3IN88US=> M2r3O3NCVkeHUh?=
NCI-H1838 MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWS5TYp{UUN3ME20OE41OzR7IN88US=> M3;lNXNCVkeHUh?=
NCI-H2405 Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPmTWM2OD12ND61N|Qh|ryP NH[yfIlUSU6JRWK=
GB-1 NGX6W3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH2VWVKSzVyPUS0Mlc1PjNizszN M{\re3NCVkeHUh?=
MG-63 NUTDepJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LYNmlEPTB;NE[uNFY6PiEQvF2= MoDRV2FPT0WU
KP-N-YN MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn3OlN6UUN3ME20Ok41Pjd7IN88US=> MnvFV2FPT0WU
no-11 MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfjWnd[UUN3ME20O{4xOjR2IN88US=> MofvV2FPT0WU
SW948 M4q1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfhTWM2OD12Nz6zN|c4KM7:TR?= MVPTRW5ITVJ?
CAMA-1 NEHyVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTR5LkO0N|gh|ryP NILDbJhUSU6JRWK=
HCC1187 M3jRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLmZ5JNUUN3ME20O{42OSEQvF2= MlmyV2FPT0WU
D-392MG NET4O4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTR5Lk[1NVYh|ryP M2\rcHNCVkeHUh?=
647-V MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnTOZZKSzVyPUS5MlM1OTRizszN MnzJV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]

Protocol

Kinase Assay:

[2]

+ Expand

MEK1 Assay:

MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research:

[1]

+ Expand
  • Cell lines: Colon 26 carcinoma cells
  • Concentrations: 0.1-10 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: PTC cells in athymic mice
  • Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water
  • Dosages: 150 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol, pH 9 10 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID